Navigation Links
Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug

An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. Khler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.

Both drugs are anti-CTLA-antibodies with similar mechanisms of action, but manufactured by different companies. Ipilimumab is an immunoglobulin G1 with a plasma half-life of 12-14 days. Tremelimumab is an immunoglobulin G2 with a plasma half-life of 22 days. Both have been extensively tested in metastatic melanoma and ipilimumab has been approved for use in patients with metastatic melanoma.

"During treatment with ipilimumab and tremelimumab, a unique set of adverse events may occur called 'immune-related adverse events,' or irAEs," said study lead author Jeffery S. Weber, M.D., Ph.D., director of Moffitt's Donald A. Adam Comprehensive Melanoma Research Center of Excellence. "These irAEs may include colitis, hepatitis, pancreatitis, lymphadenopathy, neuropathies and nephritis."

According to Weber, appropriate management of these side effects requires the cooperation of a multidisciplinary physician-led team that includes nurse practitioners and infusion nurses. Additionally, he recommends that specialists, including gastroenterologists, endocrinologists, hepatologists, dermatologists and surgeons, need education on managing these symptoms. Early recognition of irAEs and initiation of treatment are crucial, said Weber and his colleagues.

In their review of studies on the drugs' adverse effects, the researchers also found that irAEs correlated with treatment response in some studies. The reduction in tumor burden came in four different patterns after week 12 of treatment.

"Anti-CTLA-4 antibodies have shown patterns of anti-tumor response that are different from responses to conventional chemotherapy," explained Weber. "Because responses can occur slowly, or be mixed, 12 weeks has been the time to first evaluation with ipilimumab."

Weber and his colleagues also reviewed the new set of response criteria that have been created immune related response criteria or irRC to evaluate disease progression and benefit with immune checkpoint inhibitors like ipilimumab. The irRC criteria have been compared with modified WHO criteria in studies of patients receiving ipilimumab and can provide valuable information to oncologists as to when to stop treatment with ipilimumab, and when to continue.

"In this study, we provide a detailed description of irAEs and recommendations for practicing oncologists who are managing them along with the unusual kinetics of response associated with ipilimumab therapy," said Weber.


Contact: Kim Polacek
H. Lee Moffitt Cancer Center & Research Institute

Related medicine news :

1. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
2. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
3. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
4. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
5. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
6. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
7. Moffitt researchers find cutaneous human papillomavirus infection a risk factor for skin cancer
8. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
9. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
10. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
11. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock ... concert posters. This is one of Joplin's most famous and beautiful concert posters. The ... of Michigan in Ann Arbor. The According to Hawley, "It is hard to believe ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
(Date:11/26/2015)... TX (PRWEB) , ... November 26, 2015 , ... PRMA ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! ... “We wake up every day excited to rebuild lives and it’s an honor to ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
Breaking Medicine Technology: